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Abstract
Background: The present study aimed to investigate the expression of CYP27A1, CYP7B1, insulin-like growth factor-1
(IGF-1), glucose-6-phosphate-dehydrogenase (G6PD), glutathione S-transferase P1 (GSTP1), and pyruvate kinase isoform
M2 (PKM2) in breast carcinoma tissue and evaluate their prognostic value for progression-free survival (PFS) and overall
survival (OS).
Methods: A total of 20 patients treated with surgery for primary breast carcinoma were enrolled: 10 cases diagnosed
with recurrent metastasis (A), along with their corresponding metastases specimen (AM) and 10 cases with no evidence of
recurrence or metastasis (B). Baseline characteristics of patients including age, lymph node metastasis, molecular subtypes,
tumor staging and size, and pathological classification were all collected. Immunohistochemistry was performed to detect
the protein expression in tumor specimens.
Results: Elevated G6PD protein levels were noted in group A compared with group AM and B (both P < 0.05), and PKM2
expression was also higher in group A when compared to group AM (P = 0.019), but similar with group B (P > 0.05). No
association between clinicopathological parameters and the two proteins expression was observed. The G6PD protein
expression was strongly associated with PFS of breast carcinoma patients (P = 0.021) but not for OS. According to the
Kaplan-Meier analysis, mean PFS time of patients with G6PD-negative and G6PD-positive expression tumor were 71.36 ±
6.53 and 32.25 ± 5.67 months, respectively (P = 0.002).
Conclusions: The G6PD protein could be served as a potential prognostic biomarker for primary breast carcinoma, and
overexpression of G6PD protein predicted a high risk of recurrent metastasis and poor PFS during follow-up.
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Background
Breast carcinoma is the most frequent malignant tumor
in female and accounts for more than 1,000,000 new
cases annually [1]. It has been the second leading cause
of carcinoma-related death for female overall [2], with
an increasing mortality rate worldwide during the past
60 years [3]. Recently, the knowledge of cellular and mo-
lecular characteristics in breast carcinoma has facilitated
a shift toward the development of carcinoma diagnosis and
treatment [4, 5]. However, despite the new advances in the
treatment of breast carcinoma, such as the increasing ap-
plication of surgery combined with neoadjuvant chemo-
therapy or hormone therapy [6], its prognosis is poor as
the risk of recurrence or metastasis is ever present [7].
Hence, it is imperative to delineate the molecular
mechanisms underlying the recurrence or metastasis of
breast carcinoma.
Previously, España et al. has reported an association
between the metastatic activity of the cancer cells and
the regulation of glycometabolism and amino acid me-
tabolism during his study which focused on the
* Correspondence: qingyuanzhang213@hotmail.com
1Department of Medical Oncology, The Third Affiliated Hospital of Harbin
Medical University, Haping Road 150 of Nangang District, Harbin,
Heilongjiang Province 150086, China
Full list of author information is available at the end of the article
WORLD JOURNAL OF 
SURGICAL ONCOLOGY
© 2015 Pu et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International
License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any
medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative
Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://
creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Pu et al. World Journal of Surgical Oncology  (2015) 13:323 
DOI 10.1186/s12957-015-0733-0
interaction of proteins in this carcinoma cells trans-
fected with Bcl-x (L) [8]. More recently, Shidfar al. also
demonstrated that lipid metabolism genes in tumor and
contralateral unaffected breast were conversely relative
to the status of tumor estrogen receptor [9].
However, few researches focusing on the glycometabo-
lism- and lipid metabolism-related protein expression in
breast carcinoma were available. Hence, this study aimed
to investigate the expression of glycometabolism- and
lipid metabolism-related proteins in breast carcinoma,
including CYP27A1, CYP7B1, insulin-like growth factor-
1 (IGF-1), glucose-6-phosphate-dehydrogenase (G6PD),
glutathione S-transferase P1 (GSTP1), and pyruvate
kinase isoform M2 (PKM2), and to evaluate their signifi-
cance in the prognosis of this disease.
Methods
Patients
A total of 20 patients treated with total mastectomy for
primary breast carcinoma in our hospital between January
2005 and January 2014 were enrolled. The inclusion cri-
teria were as follows: (i) breast carcinoma pathologically
diagnosed with recurrent metastasis during the follow-up
(A, n = 10), along with their corresponding metastasis tis-
sue sample (AM, n = 10) and (ii) breast carcinoma with no
pathological evidence of local recurrence or metastasis
during the follow-up (B, n = 10). All the patients were
postmenopausal female. They all underwent chemother-
apy or radiotherapy as well as endocrine therapy with
arimedex after surgery. The metastasis sites included the
right mammary gland, infraclavicula, and chest wall or ac-
companied with the lung, liver, neck, or bone. The base-
line characteristics of patients including age, lymph node
metastasis, molecular subtypes, tumor staging and size, as
well as pathological classification were all collected. Pri-
mary breast carcinoma specimens of groups A and B were
sampled before chemotherapy/radiotherapy, and the me-
tastasis specimens were collected from patients who had
stopped chemotherapy/radiotherapy for at least 1 year be-
fore their recurrence during the follow-up.







Mean age (n) 0.972
≤60 years 7 7
>60 years 3 3




Molecular subtypes (n) 0.639
Luminal A 3 4
Luminal B 7 6
HER-2 0 0
Triple negative 0 0




Tumor size (cm) <0.001
≤2 cm 10 2
>2 cm 0 8
Pathological classification (n) 0.136
IDC stage I 0 2
IDC stage II 10 8
Poorly differentiated adenocarcinoma 0 0
Adenocarcinoma 0 0
Metastatic adenocarcinoma 0 0
Group A, primary breast carcinoma with recurrent metastasis during the
follow-up; Group B, primary breast carcinoma with no pathological evidence of
recurrence or metastasis; stage I, T1N0M0; stage II, T0-1N1M0, T2N0-1M0, and
T3N0M0; stage III, T0-2N2M0, T3N1-2M0, T4N0-3M0, and T0-4N3M0; IDC,
infiltrating duct carcinoma. P < 0.5 was considered statistically significant
Table 2 The expressions of CYP27A1, CYP7B1, IGF-1, G6PD,










Negative 5 8 8
Positive 5 2 2
CYP7B1 (n) 0.585
Negative 0 1 1
Positive 10 9 9
IGF-1 (n) 0.315
Negative 8 8 10
Positive 2 2 0
G6PD (n) 0.010
Negative 3 8 9
Positive 7 2 1
GFPT1 (n) 0.082
Negative 8 10 6
Positive 2 0 4
PKM2 (n) 0.036
Negative 1 6 2
Positive 9 4 8
Group A, primary breast carcinoma with recurrent metastasis during the
follow-up; Group AM, corresponding recurrent metastases; Group B, primary
breast carcinoma with no pathological evidence of recurrence or metastasis.
P < 0.5 was considered statistically significant
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Immunohistochemistry
Immunohistochemical staining was performed to detect
the expression of CYP27A1, CYP7B1, IGF-1, G6PD,
GFPT1, and PKM2 in tumor tissues. Formalin-fixed
paraffin sections (4-μm thick) of tumor specimen were
deparaffinized at 58 °C for 24 h followed by xylene I, II,
and III for 10 min, respectively, and rehydrated in a de-
scending series of alcohol (95, 85, and 75 % for 2 min, re-
spectively) and then washed three times with phosphate-
buffered saline (PBS) for 3 min. Then, they were heated
twice for antigen retrieval in 10 mM citrate buffer solution
(pH 6.0) in a microwave oven (98 °C) for 10 min. After
returning to room temperature, the sections were incu-
bated with 1 % H2O2 for 20 min or 3 % H2O2 for 5–10 min
to eliminate the endogenous peroxidase activity before
rinsing three times in PBS for 3 min. Thereafter, they
were blocked with biotinylated goat anti-rabbit immuno-
globulins (Abcam) overnight at 4 °C following rinsing
three times in PBS for 3 min. After incubation with Envi-
sion reagent for 30 min at 37 °C and rinsing three times in
PBS for 3 min, staining was revealed using 0.04 % 3,3′-di-
aminobenzidine (DAB) substrate and 0.03 % H2O2 follow-
ing tap water washing for 3 min and then counterstained
with hematoxylin for 30 s, washing, hydrochloric acid-
ethanol for 2 s, and washing. Staining with PBS in place of
primary antibody was used as negative control. The
positive staining in tumor cells exhibited buffy or brown
color with blue as background.
The percentage of stained tumor cells and the stain-
ing intensity were evaluated to semi-quantitatively de-
termine protein expression according to Li and Jiang
[10] and Dian et al. [11]. The proportion of stained
tumor cells was rated as no staining (−), <10 % staining
(+), 11–50 % staining (++), 51–75 % staining (+++),
and >75 % staining (++++). The staining intensity was
classified as no staining, weak staining, moderate stain-
ing, and strong straining. Specimen with no straining,
less than 10 % strained cells (+) or week straining were
considered as negative expression, whereas other ones
were as positive expression.
Statistical analyses
All statistical analyses were performed using SPSS 20.0
(SPSS Inc, Chicago, IL, USA), and P < 0.05 was considered
as statistically significant. Differences of the clinical char-
acteristics between patients of groups A and B and expres-
sion of glycometabolism- and lipid metabolism-related
proteins among the specimen of the three groups were an-
alyzed by χ2 test. The clinicopathologic parameters were
also analyzed in correlation to protein levels using χ2 test
between groups A and B. Cox regression analysis (Enter
method) was used to assess prognostic factors associated
with progression-free survival (PFS) time and overall sur-
vival (OS) in groups A and B. The PFS rates were calcu-
lated using the Kaplan-Meier method and Kaplan-Meier
survival curve was generated by log-rank test.
Fig. 1 Microphotographs (×400) of immunohistochemical detection of lipid metabolism-related proteins consisting of CYP27A1 (a, b, and c) and
CYP7B1 (d, e and f). a, d Primary breast carcinoma with recurrent metastasis during the follow-up. b, e Corresponding recurrent metastasis of
breast carcinoma. c, f Primary breast carcinoma with no evidence of recurrence or metastasis
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Results
The baseline characteristics of patients with primary breast
carcinoma are shown in Table 1. Patients in groups A and
B had similar age, lymph node metastasis, molecular sub-
types, and pathological classification (all P > 0.05) except for
the tumor staging and size (P = 0.043 and P < 0.001). Table 2
presents the expression of CYP27A1, CYP7B1, IGF-1,
G6PD, GFPT1, and PKM2 proteins, which were all de-
tected in the three groups of tumor tissues (Figs. 1 and 2).
As shown in Table 2, G6PD was found to be highly
expressed in the specimen of group A compared to that of
groups B and AM, respectively (P = 0.006 and P = 0.025, re-
spectively, data not shown). Interestingly, PKM2 expression
was also significantly higher in the specimen of group A
when compared to that of group AM (P = 0.019, data not
shown), but was similar with group B (P > 0.05). The speci-
mens of the three groups had similar expression of
CYP27A1, CYP7B1, IGF-1, and GFPT1 (all P > 0.05).
Furthermore, Table 3 showed that the G6PD expres-
sion in tumor tissue was not associated with age, lymph
node metastasis, molecular subtypes, tumor staging and
size, as well as pathological classification (all P > 0.05).
However, the PKM2 expression was relative to lymph
node metastasis (P = 0.001). The variables with P < 0.05
between groups A and B were included in the Cox
regression analysis (Enter method). Multivariate survival
analysis indicated that only G6PD expression (hazard
ratio = 13.488, P = 0.021) was an independent prognostic
factor for mean PFS time (Table 4), suggesting that the
primary breast carcinoma patients with upregulated
G6PD expression were more likely to have poor PFS sur-
vival due to local recurrence or metastasis. However,
PKM2 expressions in cancer tissue and tumor staging
and size did not influence mean PFS time (all P > 0.05).
Besides, all the variables had no effect on OS time (all
P > 0.05). According to the Kaplan-Meier analysis, the
Fig. 2 Microphotographs (×400) of immunohistochemical detection of glycometabolism-related proteins, including IGF-1 (a, b, and c), G6PD (d,
e, and f), GSTP1 (g, h, and i), and PKM2 (j, k, and l). a, d, g, j Primary breast carcinoma with recurrent metastasis during the follow-up. b, e, h, k
Corresponding recurrent metastasis of breast carcinoma. c, f, i, l Primary breast carcinoma with no evidence of recurrence or metastasis
Pu et al. World Journal of Surgical Oncology  (2015) 13:323 Page 4 of 7
mean PFS times of patients with G6PD-negative and
G6PD-positive expression tumor were 71.36 ± 6.53 and
32.25 ± 5.67 months, respectively (Fig. 3, log-rank test,
P = 0.002).
Discussion
Despite many reports regarding the prognostic factors of
breast carcinoma [11–16], few studies have focused on
the expression of various glycometabolism- and lipid
metabolism-related proteins among primary breast
carcinoma diagnosed with recurrent metastasis during
the follow-up, the corresponding recurrent metastasis,
and primary breast carcinoma with good prognosis yet.
In the present study, we conducted a retrospective ana-
lysis on the expression of CYP27A1, CYP7B1, IGF-1,
G6PD, GFPT1, and PKM2 proteins in cancer tissues
from 20 cases of primary breast carcinoma, among
whom 10 cases were diagnosed with recurrent metas-
tasis and 10 cases had no evidence of recurrence or
metastasis during their follow-up. The results showed
that G6PD protein was significantly associated with
prognosis in PFS.
G6PD, as the first rate-limiting enzyme of the pentose
phosphate pathway (PPP), has been proved associated
with the regulation of cell proliferation and transform-
ation [17, 18]. The elevated G6PD activities were observed
in various human cancers, such as renal cell carcinoma
[19], bladder cancer [20], as well as gastric cancer [21]. In
this study, we also identified an abnormally elevated expres-
sion of G6PD protein in primary breast carcinoma tissues
with a positive follow-up of metastasis compared with cor-
responding recurrent metastases and primary breast carcin-
oma tissues with no evidence of recurrence or metastasis
during follow-up, suggesting that G6PD overexpression
might be responsible for cancer recurrent metastases. The
elevated PKM2 expression in primary breast carcinoma di-
agnosed with recurrent metastasis relative to metastases
might also reveal a possible inhibitive effect of low PKM2
Table 3 Correlation between clinicopathological features and
the protein expression of G6PD and PKM2 in patients with
breast carcinoma
Indicators G6PD P value PKM2 P value
Negative Positive Negative Positive
Mean age (n) 0.111 0.891
≤0 years 10 4 2 12




0 2 2 3 1
≤3 4 3 0 9




Luminal A 5 2 1 6




I 0 3 1 2
II 7 2 2 7
III 5 3 0 8
Tumor size (n) 0.070 0.306
≤2 cm 5 7 1 11




IDC stage I 2 0 0 2
IDC stage II 10 8 3 15
Stage I, T1N0M0; stage II, T0-1N1M0, T2N0-1M0, and T3N0M0; stage III, T0-2N2M0,
T3N1-2M0, T4N0-3M0, and T0-4N3M0; IDC, infiltrating duct carcinoma. P < 0.5 was
considered statistically significant
Table 4 Multivariate analyses of progression-free survival (PFS) and overall survival (OS) in patients with breast carcinoma
Variables PFS OS
P value Hazard ratio (HR) 95 % CI P value HR 95 % CI
G6PD (negative vs. positive expression) 0.021 13.488 1.472–123.554 0.398 2.695 0.271–26.815
PKM2 (negative vs. positive expression) 0.835 1.304 0.107–15.868 0.674 1.916 0.093–39.686
Tumor staging
I 0.095 0.977
II 0.241 0.262 0.028–2.461 0.963 – –
III 0.375 2.691 0.303–23.938 0.964 – –
Tumor size (≤2 cm vs. >2 cm) 0.946 0.000 – 0.900 – –
Cox regression analysis (Enter method) was used to assess prognostic factors associated with PFS and OS. A hazard ratio >1 with P < 0.05 indicates a greater
likelihood of development of breast carcinoma, while a hazard ratio <1 with P < 0.05 indicates a lesser likelihood of development of breast carcinoma. A hazard
ratio = 1 with P < 0.05 indicates that the given factor could not affect the development of breast carcinoma, but was significant in multivariate logistic
regression model
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expression on recurrent metastasis. However, this inhibitive
effect was significantly affected by lymph node metastasis
(P = 0.001), that is, the similar expression of PKM2 in pri-
mary breast carcinoma tissues with and without evidence
of recurrent metastasis might be attributed to the similar
lymph node metastasis between the two groups. In the
work by Wang et al., G6PD protein in cancer tissue was
found dependent on the tumor size and lymph node
metastasis [21]; however, it was not witnessed in our study.
The inconsistent results were probably due to the different
cancer types and research conditions.
Furthermore, Cox multivariate analyses indicated that
the G6PD protein was an independent prognostic fac-
tor for mean PFS, consistent with previous study. Pa-
tients with low expression of G6PD were more likely to
live longer with no recurrence or metastasis, which was
evidenced by the Kaplan-Meier survival curves (P =
0.002). Based on the above results, it seemed that a de-
termination of G6PD expression before surgery might
be of great importance in predicting the therapeutic ef-
fect and postoperative PFS for patients with primary
breast carcinoma.
Several limitations to this study must be addressed.
First, the cases of patients with recurrent metastasis
were insufficient because the specimen were difficult
to collect from recurrent metastases (most at infracla-
vicula and chest wall), and it might affect the statis-
tical accuracy. Second, control comparisons within
each patient (normal tissue vs. malignant tissue), HIF
protein expression, and real-time reverse transcriptase
polymerase chain reaction (RT-PCR) were not per-
formed. However, under this perspective, our prelim-
inary finding could lead to a broader line of research
for further validation.
Conclusions
In conclusion, this study did demonstrate that the over-
expression of G6PD in primary breast carcinomas was
associated with a high risk of recurrent metastasis and
poor PFS. Further studies were certainly needed for this
issue on a large number of patients with primary breast
carcinomas and to clarify the role of G6PD protein or
other else in breast cancer progression.
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